C23H24N4O4
420.5 g/mol
APIWarning
Brensocatib
CAS1802148-05-5
Category
API
Compound Class
Amide
Primary Use
Pharmaceutical Raw Material
Brensocatib is a pharmaceutical raw material and a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor. It is used in the manufacturing of compounds targeting neutrophilic inflammation in chronic lung diseases such as non-cystic fibrosis bronchiectasis.
pharmaceutical manufacturing intermediateresearch compound for DPP1 inhibition studies
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Brensocatib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Related Compounds
ReferenceSame Category
Repotrectinib
CAS1802220-02-5
pharmaceutical raw material
ReferenceSame Category
Ferric pyrophosphate citrate
CAS1802359-96-1
pharmaceutical raw material
ReferenceSame Category
Milvexian
CAS1802425-99-5
pharmaceutical raw material
ReferenceSame Category
Filgotinib maleate
CAS1802998-75-9
pharmaceutical raw material
Safety Reference
Warning
H373May cause damage to organs through prolonged or repeated exposure
Customs Tariff Classification
The international HS code for Brensocatib (CAS 1802148-05-5) is 2934.99.
HS code (international, 6-digit)
2934.99
EU CN code (8-digit)
2934 99 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
Identifiers
IUPAC Name
(2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
InChIKey
AEXFXNFMSAAELR-RXVVDRJESA-N
SMILES
CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
Synonyms (8)
- Brensocatib (USAN/INN)
- AZD7986;INS 1007
- Brinsupri
- brensocatib
Sourcing Brensocatib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.